The Funnel of Attrition
Drug discovery is a process of extreme elimination. The journey begins with thousands of potential compounds identified in the lab. Through rigorous preclinical testing and three phases of human trials, nearly every candidate fails due to toxicity or lack of efficacy.
This chart visualizes the sheer scale of candidate loss. Note the logarithmic drop-off from the Discovery phase to final FDA Approval.
Compounds remaining at each stage (Log Scale Visual Representation)
Navigating the "Valley of Death"
Surviving preclinical studies is just the beginning. The probability of success (PoS) varies wildly by clinical phase. phase 2 is notoriously known as the "Valley of Death," where the majority of drugs fail to demonstrate proof-of-concept efficacy in patients. (Hover over phases for details)
Is it Safe?
Small trials (20-100 volunteers) focused on safety, dosage, and pharmacokinetics.
Does it Work?
The critical inflection point. Efficacy testing in patients (100-300). 33% Success Rate.
Is it Better?
Large scale (1,000+) trials vs standard of care. The most expensive phase.
Commercialization.
FDA review and launch. < 0.01% of discovery compounds reach here.
Clinical Trial Activity
A real-time snapshot of active clinical trials across major biotech companies. Data is sourced directly from clinicaltrials.gov, highlighting the volume of R&D activity per ticker. -1 : 'N/A', 0 : 'Early Phase 1'.
Hypothetical Valuation Curve based on De-Risking Events
The Step-Function of Value (rNPV)
Biotech valuation does not follow a linear path. Instead, it follows a Step-Function. Value is essentially flat or slowly declining (burn rate) between major data readouts.
Investors use Risk-Adjusted Net Present Value (rNPV). This model explicitly discounts future cash flows based on the probability of success (PoS) at the current development stage.
When positive data is released (e.g., Phase 2 Success), the risk of failure drops dramatically, causing the rNPV to spike instantly. This is why biotech stocks are so volatile around binary events.
Key Investor Questions
-
1.
Pipeline Depth: Is there a "second shot on goal" if the lead candidate fails?
-
2.
Cash Runway: Does the company have enough cash to reach the next meaningful data readout?
-
3.
Differentiation: Is this a "me-too" drug or a first-in-class mechanism with clear clinical advantages?
- De-Risking: Each success increases the probability variable in the NPV equation.
- Binary Events: PDUFA dates and trial readouts create massive inflection points.
Startup Survival Strategy
How do small biotechs survive without revenue for 10 years? They rely on three strategic pillars to navigate the long road to commercialization.
IP Moat
Patents are the product. Without a "patent estate" guaranteeing 20 years of exclusivity, no investor will fund the research. Startups must aggressively file composition and method-of-use patents.
Non-Dilutive Funding
Smart founders avoid giving up equity too early. They leverage NIH grants, BARDA funding, and patient advocacy groups to fund early preclinical work before seeking Venture Capital.
The Virtual Model
Many modern biotechs have no labs. They operate virtually, outsourcing experiments to Contract Research Organizations (CROs). This keeps burn rates low and agility high.
Case Study: Nocion Therapeutics
Nocion exemplifies the model success. Founded on licensed IP from Harvard, they secured a $62M Series B explicitly to fund a Phase 2b trial.
- ✓ Validated Target (Sodium Channels)
- ✓ High Unmet Need (Chronic Cough)
- ✓ Strategic Milestone Financing
The Flipside: Failure
Failure often stems from over-interpreting Phase 2 biomarkers (e.g., Torcetrapib) or misunderstanding biology (e.g., Semagacestat in Alzheimer's).